Medical sector’s DURECT’s (NASDAQ:DRRX) Buy rating Reiterated by B. Riley

0
26
Stock Market Data/chart illustration

DURECT (NASDAQ:DRRX)‘s stock had its Buy rating Reiterated by analysts at B. Riley in a research report issued to clients and investors. A price-to-earnings ratio of #N/A, market cap of 490.1M and a beta of 2.2.  DURECT has a twelve month low $0.60 of  and a twelve month high of $3.95.

Shares of DURECT traded up $0.05 on Monday, reaching $2.50. 1141356 shares of the stock traded hands, compared to its average volume of 2177992. Shares of DURECT at mid-way of the day on Monday were at $2.50. The firm’s 50 day moving average is $$2.32 and its 200 day moving average is $2.05.DURECT  has a 12 month low of $2.30 and a 12 month high of $3.95. While on yearly highs and lows, DURECT’s today has traded high as $2.51 and has touched $2.30 on the downward trend. See More Analyst Rating at: RATING

DURECT (NASDAQ:DRRX) Moving Average Technical Analysis

5 day Moving Average is $2.46 And 5 day price change is unch (unch)  with average volume for 5 day average is 6,703,096. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $2.38 and 20 day price change is -$0.03 (-1.22%) and average 20 day moving volume is 2,547,294. 50 day moving average is $2.32  and 50 day price change is $0.47 ( 24.10%)  and with average volume for 50 days is : 1,664,954. 200 day moving average is $2.05  and 200 day price change is $0.70 (40.70%)  and with average volume for 200 days is : 1,302,963.

See More Analyst Rating at: RATING

DURECT Earnings and What to expect: 

DURECT last posted its quarterly earnings data on May 11th, 2020. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.01. The company earned $2.78 million during the quarter, compared to analysts’ expectations of $4.74 million. DURECT has generated ($0.12) earnings per share over the last year. DURECT has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, August 6th, 2020 based off prior year’s report dates.

Earnings for DURECT are expected to grow in the coming year, from ($0.18) to ($0.13) per share. The P/E ratio of DURECT is -20.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of DURECT is -20.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. DURECT has a P/B Ratio of 20.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 10.20%
  • On 6/3/2020 VP Judy R Joice Sell 57,820 at average share price of $2.45 which equates to $141,659.00 in money value.
  • On 5/26/2020 Major Shareholder Lp Bleichroeder Sell 39,388 at average price of  $2.50 with total value of : Not Data Available
  • On 2/6/2020 Major Shareholder Lp Bleichroeder Buy 227,498 at average price of  $1.63 with total value of : $370,821.74

What other brokers have to say about DURECT :

  • 5/30/2020 – DURECT was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 5/27/2020 – DURECT had its price target raised by analysts at HC Wainwright from $5.50 to $6.00. They now have a “buy” rating on the stock.
  • 5/26/2020 – DURECT had its “buy” rating re-affirmed by analysts at B. Riley. They now have a $5.00 price target on the stock.
  • 5/12/2020 – DURECT had its “buy” rating re-affirmed by analysts at B. Riley. They now have a $5.00 price target on the stock.

Other firm’s rating by B. Riley:

  • 6/29/2020 – Novavax had its price target raised by analysts at B. Riley from $74.00 to $106.00. They now have a “buy” rating on the stock.
  • 6/26/2020 – Cinemark had its “hold” rating re-affirmed by analysts at B. Riley. They now have a $16.00 price target on the stock.
  • 6/26/2020 – Marcus had its “hold” rating re-affirmed by analysts at B. Riley. They now have a $15.00 price target on the stock.
  • 6/26/2020 – Nanometrics had its “buy” rating re-affirmed by analysts at B. Riley. They now have a $46.00 price target on the stock.

See More Analyst Rating at: RATING